Table 1.
TSP1 active anti-angiogenic peptides
| Source | Domain | Sequence | Receptor | Mechanism |
|---|---|---|---|---|
| TSP1 | N-ter, heparin binding (25K) | Heparin | Internalizes VEGF, decreases VEGFR2, induces apoptosis [1] | |
| TSP1 | TSR2 | SPWSSCSVTCGDGVITRIR | CD36 | Apoptosis [2–4] |
| TSP1 | TSR2 | KRFKQDGGWSHWSPWSSC | Heparin | activates TGFβ [5, 6] quenches VEGF [7] |
| TSP1 | Procollagen + 3 TSR | CD36 | Apoptosis [8, 9] | |
| TSP2 | Procollagen + 3 TSR | CD36? | Apoptosis [10] | |
| TSP1 | 3 TSR | CD36 β1 integrin | Apoptosis [11–13] | |
| TSP1 | TSR2 | SPWSSCSVTCGDGVdITRIR (DI-TSP) | CD36 | Apoptosis [14] |
| TSP1 | TSR2 | Ac-Sar-GVdITNvdIR-NHEt (ABT-510) | CD36 | Apoptosis [15] |
| TSP1 | TSR2 | Ac-Sar-GVd-allo-ITNvdIR- NHEt (ABT-526) | CD36 | Apoptosis [15] |
Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). Journal of cellular physiology. Mar 2007;210(3):807–818.
Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. The Journal of cell biology. Jul 1993;122(2):497–511.
Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer research. May 1 1997;57(9):1735–1742.
Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. Sep 28 1999;100(13):1423–1431.
Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. The Journal of biological chemistry. May 7 1999;274(19):13586–13593.
Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. Jun 26 1998;93(7):1159–1170.
Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, Taraboletti G. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood. Dec 15 2003;102(13):4399–4406.
Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J, Detmar M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. The American journal of pathology. Aug 1999;155(2):441–452.
Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. The American journal of pathology. Aug 2004;165(2):541–552.
Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. The international journal of biochemistry & cell biology. Jun 2004;36(6):1038–1045.
Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res. Aug 1 2005;11(15):5622–5630.
Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res. Mar 15 2005;11(6):2337–2344.
Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. The Journal of cell biology. Feb 14 2005;168(4):643–653.
Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Molecular pharmacology. Feb 1999;55(2):332–338.
Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, Henkin J. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. Journal of medicinal chemistry. Apr 21 2005;48(8):2838–2846.